NSCLC diagnostic standards has included the detection of epidermal growth factor receptor (EGFR), B-Raf proto-oncogene (BRAF), MET proto-oncogene (MET), erb-b2 receptor tyrosine kinase 2 (ERBB2), and erb-b2 receptor tyrosine kinase 2 (KRAS) mutations (3). Here, MET is linked to non-small cell lung carcinoma.